Shen Yao-Hua, Yang Fan, Jin Li-Dan, Qian Yu-Jia, Xing Li, Huang Ya-Li, Lin Su-Feng, Xiao Fei
Department of Anesthesia, Hangzhou City Linping District Maternal and Child Care Hospital, Hangzhou, China.
Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Bio-X Institutes, Shanghai Jiao Tong University, Shanghai, China.
Front Pharmacol. 2021 Oct 20;12:720906. doi: 10.3389/fphar.2021.720906. eCollection 2021.
Studies involving mouse models and human uterine smooth muscle cells have shown that phenylephrine inhibits uterine contractions in non-pregnant mice and human cell cyclic adenosine monophosphate (cAMP) signaling. However, there has been no limited exploration to date of the effect of phenylephrine on uterine contractions in clinical practice. This study aimed to compare the dose requirement of oxytocin with or without the infusion of prophylactic phenylephrine to prevent post spinal hypotension during cesarean delivery under combined spinal and epidural anesthesia. This was a double-blinded, single-center, randomized, control study. One hundred and sixty pregnant patients provided informed consent and were randomly allocated to the phenylephrine (phenylephrine infusion) and control (saline infusion) groups. Patients randomized to the phenylephrine group received an intravenous prophylactic phenylephrine infusion at a fixed rate of 0.5 μg/kg/min. The control group received a saline placebo at the same rate and used the same apparatus for delivery. After neonatal delivery and clamping of the umbilical cord, patients received a standard institutional oxytocin protocol. The primary outcome measure was the total dose of oxytocin administered during CD. Secondary outcomes including the proportion (%) of patients requiring a secondary uterotonic agent and estimated blood loss (EBL) in the first 24 h after surgery. The median oxytocin dose administered was significantly higher in the phenylephrine group than in the control group [6.9 ± 2.5 international standardized units (IU) 5.4 ± 2.4 IU, = 0.0004]. The number of patients that required a secondary uterotonic agent was significantly higher in the phenylephrine group than in the control group (24.2% 9.1%; = 0.034). The EBL in the first 24-h postoperatively was similar between the two groups (467 ± 47 ml 392 ± 38 ml; = 0.22). Prophylactic infusion of phenylephrine used to prevent post-spinal hypotension during CD was associated with a higher dose of oxytocin. This has important clinical implications, as the suboptimal use of oxytocin is associated with an increased risk of postpartum hemorrhage and increased maternal morbidity and mortality. Further studies are now needed to confirm these findings.
涉及小鼠模型和人子宫平滑肌细胞的研究表明,去氧肾上腺素可抑制未孕小鼠的子宫收缩以及人细胞中环磷酸腺苷(cAMP)信号传导。然而,迄今为止,在临床实践中,对于去氧肾上腺素对子宫收缩的影响探索有限。本研究旨在比较剖宫产腰麻-硬膜外联合麻醉时,输注或不输注预防性去氧肾上腺素预防脊麻后低血压所需缩宫素的剂量。这是一项双盲、单中心、随机对照研究。160例孕妇签署知情同意书后,被随机分为去氧肾上腺素组(输注去氧肾上腺素)和对照组(输注生理盐水)。随机分配至去氧肾上腺素组的患者以0.5μg/kg/min的固定速率静脉输注预防性去氧肾上腺素。对照组以相同速率输注生理盐水安慰剂,并使用相同的给药装置。新生儿娩出并钳夹脐带后,患者接受标准的机构缩宫素方案。主要观察指标为剖宫产期间给予缩宫素的总剂量。次要观察指标包括术后24小时内需要使用第二剂宫缩剂的患者比例(%)以及估计失血量(EBL)。去氧肾上腺素组给予缩宫素的中位剂量显著高于对照组[6.9±2.5国际单位(IU)对5.4±2.4 IU,P=0.0004]。去氧肾上腺素组需要使用第二剂宫缩剂的患者数量显著高于对照组(24.2%对9.1%;P=0.034)。两组术后24小时内的EBL相似(467±47 ml对392±38 ml;P=0.22)。剖宫产时用于预防脊麻后低血压的预防性去氧肾上腺素输注与更高剂量的缩宫素相关。这具有重要的临床意义,因为缩宫素使用不当与产后出血风险增加以及孕产妇发病率和死亡率增加有关。现在需要进一步研究来证实这些发现。